Company news

Lexicon Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023

April 27, 2023

Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023

April 20, 2023

Lexicon Pharmaceuticals to Participate in The 22nd Annual Needham Virtual Healthcare Conference

April 16, 2023

Lexicon Reveals “INTO THE DARK” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization

March 3, 2023

Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update

March 1, 2023

Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia

December 20, 2022

Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit

November 13, 2022

Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update

November 8, 2022

Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022

October 23, 2022

Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement

August 4, 2022

Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

August 1, 2022

Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022

July 28, 2022

Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement

July 27, 2022

Lexicon Announces Proposed Public Offering Of Common Stock

July 26, 2022

Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure

July 26, 2022

Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy

June 28, 2022

Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure

May 30, 2022

Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update

May 4, 2022

Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022

February 27, 2022

Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Clinical Update

February 27, 2022

Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes

December 29, 2021

Lexicon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical Update

November 2, 2021

Craig Granowitz, M.D., Ph.D. Joins Lexicon as Senior Vice President and Chief Medical Officer

July 29, 2021

Lexicon Pharmaceuticals to Host Second Quarter 2021 Financial Results Conference Call and Webcast on July 30, 2021

July 27, 2021

Lexicon Pharmaceuticals Announces Symposium at the American Diabetes Association 81st Scientific Sessions

June 24, 2021

Lexicon Pharmaceuticals Announces Two Presentations at the American College of Cardiology’s 70th Annual Scientific Session

May 12, 2021

Lexicon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical Update

May 5, 2021

Lexicon Pharmaceuticals to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 6, 2021

April 28, 2021

Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Clinical Update

March 9, 2021

Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast on March 10, 2021

March 3, 2021

Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure

January 13, 2021

Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia

December 30, 2020

Lexicon Announces Offering of Common Stock

December 10, 2020

Lexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical Update

October 28, 2020

Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness

September 22, 2020

Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera Therapeutics

September 7, 2020

Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain

September 3, 2020

Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

July 29, 2020

Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes

July 20, 2020

Lexicon Pharmaceuticals Announces Poster Presentations at the Virtual Cholangiocarcinoma Foundation Annual Conference

July 19, 2020

Lexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyl’s Antiproliferative Effects Against Various Cancer Cell Lines

May 12, 2020

Lexicon Pharmaceuticals reports first quarter 2020 financial results and provides a business update

April 26, 2020

Lexicon Pharmaceuticals to host virtual annual meeting of stockholders on April 23, 2020

April 6, 2020

Lexicon Pharmaceuticals provides an update on the sotagliflozin type 2 diabetes program

March 18, 2020

Lexicon Pharmaceuticals announces additional data on telotristat ethyl’s antiproliferative effects in patients with carcinoid syndrome

March 12, 2020

Lexicon Pharmaceuticals reports fourth quarter and full-year 2019 financial results and provides a business update

March 11, 2020

Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl’s Antiproliferative Effects in Patients With Carcinoid Syndrome

January 23, 2020

Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium

January 19, 2020

Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes

December 19, 2019

Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211

December 4, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 23 decks. Every deck is listed under its year.